Article Text

PDF
Original research
Closure of large bore 9 F arterial puncture sites with the AngioSeal STS device in acute stroke patients after intravenous recombinant tissue plasminogen activator (rt-PA)
  1. Hendrik Janssen1,
  2. Monika Killer-Oberpfalzer2,
  3. Ruediger Lange3
  1. 1Department of Neuroradiology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany
  2. 2Neurology/Research Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria
  3. 3Department of Neurology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany
  1. Correspondence to Dr Hendrik Janssen, Department of Neuroradiology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg 90471, Germany; hendrik.janssen{at}klinikum-ingolstadt.de

Abstract

Purpose This retrospective analysis was performed to evaluate whether large bore 9 F puncture sites can be safely closed with the 8 F AngioSeal STS device after endovascular stroke procedures in patients who did or did not receive recombinant tissue plasminogen activator (rt-PA).

Methods Out of 161 consecutive endovascular stroke procedures we identified 72 patients who met the inclusion criteria, of whom 46 received rt-PA before the endovascular procedure and 26 did not. All groin complications such as major haemorrhage, failure of the device to close the puncture site, delayed haemorrhage, acute lower extremity ischaemia or necessary vascular surgery as well as infections were recorded.

Results Only one patient had delayed groin haemorrhage after closure of the 9 F puncture site with the AngioSeal STS device. There was no significant difference in complications between patients with or without rt-PA treatment.

Conclusion The 8 F AngioSeal STS seems to be safe and efficient to close 9 F femoral artery puncture sites, even under active rt-PA thrombolysis.

  • stroke
  • technique

Statistics from Altmetric.com

Footnotes

  • Contributors HJ and RL: study conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript. MK-O: study conception and design, critical revision of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests HJ is consultant for MicoVention, Inc. MK-O received a research grant from MicroVention, Inc and is consultant for Medtronic and MicroVention, Inc.

  • Patient consent Not required.

  • Ethics approval Bayrische Landesärztekammer.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.